Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher Completes Dionex Buy, Acquires Sterilin

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Thermo Fisher Scientific said after the close of the market on Tuesday that it has completed the $2.1 billion purchase of chromatography firm Dionex through a short-form merger.

Today, Thermo Fisher also announced it has acquired Sterilin, a provider of single-use plastic products, for an undisclosed amount.

Pursuant to the terms of the Dionex merger, all shares of the company will be exchanged for $118.50 per share. Dionex's stock ceased trading on Nasdaq after the close of the market today, and will be delisted.

Thermo Fisher had completed the tender offer for Dionex last Friday, following clearance from the European Union.

Commenting on the Sterilin acquisition, Marc Casper, president and CEO of Thermo Fisher, said in a statement that it broadens the range of specialty laboratory products that the firm offers. The business will be integrated into Thermo Fisher's Laboratory Products and Services segment.

Based in South Wales, UK, Sterilin posted $35 million in revenues in 2010 and has about 270 employees. Its products serve the microbiology, life sciences, and clinical markets.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.